Pharmacological inhibition of NLRP3 inflammasome activation and IL-1β production with specific antagonists, such as MCC950, has exhibited plausible effects on preventing neurological impairment of multiple sclerosis, neurodegenerative diseases, and traumatic brain injury [25–27]. Here, NLRP3 is linked to multiple sclerosis.